193 related articles for article (PubMed ID: 37008735)
21. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment.
Zhang P; Qin C; Liu N; Zhou X; Chu X; Lv F; Gu Y; Yin L; Liu J; Zhou J; Huo M
Biomaterials; 2022 May; 284():121518. PubMed ID: 35462305
[TBL] [Abstract][Full Text] [Related]
22. Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer.
Liu Y; Qiu N; Shen L; Liu Q; Zhang J; Cheng YY; Lee KH; Huang L
J Control Release; 2020 Jul; 323():431-441. PubMed ID: 32360890
[TBL] [Abstract][Full Text] [Related]
23. Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer.
Wu W; Xu M; Qiao B; Huang T; Guo H; Zhang N; Zhou L; Li M; Tan Y; Zhang M; Xie X; Shuai X; Zhang C
Acta Biomater; 2023 Mar; 158():547-559. PubMed ID: 36539109
[TBL] [Abstract][Full Text] [Related]
24. Nano-puerarin regulates tumor microenvironment and facilitates chemo- and immunotherapy in murine triple negative breast cancer model.
Xu H; Hu M; Liu M; An S; Guan K; Wang M; Li L; Zhang J; Li J; Huang L
Biomaterials; 2020 Mar; 235():119769. PubMed ID: 31986348
[TBL] [Abstract][Full Text] [Related]
25. Targeting therapy and tumor microenvironment remodeling of triple-negative breast cancer by ginsenoside Rg3 based liposomes.
Xia J; Zhang S; Zhang R; Wang A; Zhu Y; Dong M; Ma S; Hong C; Liu S; Wang D; Wang J
J Nanobiotechnology; 2022 Sep; 20(1):414. PubMed ID: 36109762
[TBL] [Abstract][Full Text] [Related]
26. Enhancing TNBC Chemo-immunotherapy via combination reprogramming tumor immune microenvironment with Immunogenic Cell Death.
Wu S; Liu D; Li W; Song B; Chen C; Chen D; Hu H
Int J Pharm; 2021 Apr; 598():120333. PubMed ID: 33540008
[TBL] [Abstract][Full Text] [Related]
27. Nano-delivery of fraxinellone remodels tumor microenvironment and facilitates therapeutic vaccination in desmoplastic melanoma.
Hou L; Liu Q; Shen L; Liu Y; Zhang X; Chen F; Huang L
Theranostics; 2018; 8(14):3781-3796. PubMed ID: 30083259
[No Abstract] [Full Text] [Related]
28. Copper-induced injectable hydrogel with nitric oxide for enhanced immunotherapy by amplifying immunogenic cell death and regulating cancer associated fibroblasts.
Shen S; Zhang Z; Huang H; Yang J; Tao X; Meng Z; Ren H; Li X
Biomater Res; 2023 May; 27(1):44. PubMed ID: 37165428
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
30. Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy.
Wang Z; Cordova LE; Chalasani P; Lu J
Mol Pharm; 2022 Dec; 19(12):4665-4674. PubMed ID: 36413426
[TBL] [Abstract][Full Text] [Related]
31. Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo.
Mardhian DF; Storm G; Bansal R; Prakash J
J Control Release; 2018 Nov; 290():1-10. PubMed ID: 30287265
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review.
Eskandari-Malayeri F; Rezaei M
Front Immunol; 2022; 13():996145. PubMed ID: 36275750
[TBL] [Abstract][Full Text] [Related]
34. Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy.
Hu M; Wang Y; Xu L; An S; Tang Y; Zhou X; Li J; Liu R; Huang L
Nat Commun; 2019 Jul; 10(1):2993. PubMed ID: 31278269
[TBL] [Abstract][Full Text] [Related]
35. Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1
Gok Yavuz B; Gunaydin G; Gedik ME; Kosemehmetoglu K; Karakoc D; Ozgur F; Guc D
Sci Rep; 2019 Feb; 9(1):3172. PubMed ID: 30816272
[TBL] [Abstract][Full Text] [Related]
36. Remodels the Immunosuppressive Tumor Microenvironment by Combination of Bacillus Calmette-Guérin and Anti-PD-L1 in an Orthotopic Triple-Negative Breast Cancer Mouse Model.
Lu Y; Huang X; Liu X; He Y; Hu Z; Xu W; Cao G; He W
Onco Targets Ther; 2021; 14():2247-2258. PubMed ID: 33833524
[TBL] [Abstract][Full Text] [Related]
37. Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.
Chaurasiya S; Yang A; Kang S; Lu J; Kim SI; Park AK; Sivanandam V; Zhang Z; Woo Y; Warner SG; Fong Y
Oncoimmunology; 2020; 9(1):1729300. PubMed ID: 32158622
[TBL] [Abstract][Full Text] [Related]
38. Relaxin gene delivery modulates macrophages to resolve cancer fibrosis and synergizes with immune checkpoint blockade therapy.
Zhou X; Liu Y; Hu M; Wang M; Liu X; Huang L
Sci Adv; 2021 Feb; 7(8):. PubMed ID: 33597232
[TBL] [Abstract][Full Text] [Related]
39. Nano-baicalein facilitates chemotherapy in breast cancer by targeting tumor microenvironment.
Zheng F; Luo Y; Liu Y; Gao Y; Chen W; Wei K
Int J Pharm; 2023 Mar; 635():122778. PubMed ID: 36842519
[TBL] [Abstract][Full Text] [Related]
40. Combination of oxymatrine (Om) and astragaloside IV (As) enhances the infiltration and function of TILs in triple-negative breast cancer (TNBC).
Wang H; Wei L; Mao D; Che X; Ye X; Liu Y; Chen Y
Int Immunopharmacol; 2023 Dec; 125(Pt A):111026. PubMed ID: 37866315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
